About KiuClavis
A dual-graph precision oncology platform synthesizing regulatory-grade clinical truth with exploratory preclinical discovery — mathematically anchored by the Nesatz epistemic foundation.
"The platform couples Clavis (Latin for key), an exploratory knowledge graph traversing preclinical hypotheses and chemical space, with Kiu (welcome rain after drought), a canonical graph restricted strictly to peer-reviewed consensus, regulatory approvals, and clinical trial evidence — unified and guarded by Nesatz."
Our Mission
Modern biomedical information systems face a critical epistemic failure: the conflation of speculative preclinical hypotheses with validated clinical standard-of-care. Generative AI models consistently blend in vitro correlations, unverified cell-line assays, and early preprints directly into clinical summaries, creating severe hallucination risks in oncology decision workflows.
KiuClavis eliminates this risk through architectural partitioning rather than heuristic prompt engineering. By decoupling preclinical hypothesis traversal (The Clavis Lens) from clinical trial and FDA regulatory evidence (The Kiu Lens), oncologists and translational researchers navigate complex molecular spaces with absolute evidentiary clarity.
Dual-Graph Architectural Separation
Two distinct evidentiary graphs operating under strict non-interference guarantees.
Canonical Clinical Evidence
The authoritative layer restricted exclusively to confirmed clinical realities, regulatory label truth, and prospective trials.
- FDA / EMA Package Inserts: Deterministic approval indications and contraindications.
- Phase I-III Clinical Trials: Registered data verified against ClinicalTrials.gov endpoints.
- Companion Diagnostics (CDx): Formally mandated biomarker diagnostic assays.
- Strict Monotonicity: Prohibits promotion of unproven hypotheses into clinical truth.
Preclinical Mechanistic Frontier
The exploratory shadow knowledge graph traversing signaling pathway convergence, novel chemical biology, and resistance dynamics.
- Pathway Convergence: MAPK/ERK, PI3K/AKT/mTOR, and immuno-oncology signaling.
- Resistance Topologies: Secondary on-target mutations and bypass track activation.
- Synthetic Lethality: Experimental drug combinations and synthetic lethal targets.
- Isolated Shadow Graph: Exploratory claims tagged with epistemic bounds and premise logs.
Grounded by Nesatz
Data integrity in KiuClavis is enforced by Nesatz (@nesatz/core), an epistemic sovereignty engine providing mathematical invariant enforcement, cryptographic provenance anchoring, and immutable transactional audit logging.
Pre-read syntax filtering, AST injection blocking, and untrusted payload neutralization.
Mathematical count conservation: ORR = CR + PR, DCR ≥ ORR, plus strict epistemic modality checks.
Pre-write dry-run simulation and state machine validation to prevent race conditions.
Cryptographic SHA-256 hash validation against primary source texts (PubMed, CDx, CFR).
Post-write drift verification with tamper-evident audit logging stored in Neon Postgres.
Sample Query Document: "STK11 Mutation in NSCLC"
Live constitutional verification trace executing through KiuClavis and Nesatz.
STK11 (LKB1) encodes a master serine/threonine kinase regulating cellular energy metabolism. In Non-Small Cell Lung Cancer (NSCLC), concurrent STK11 and KRAS mutations define an immunologically "cold" microenvironment with reduced PD-L1 expression and poor CD8+ T-cell infiltration.
- Warning: STK11 mutations are a validated negative predictive biomarker for Pembrolizumab or Nivolumab single-agent checkpoint blockade [Level 1 Evidence, KEYNOTE-042].
- Recommended Protocol: Standard of care escalates to platinum-doublet chemotherapy combined with anti-PD-(L)1 regimens, or enrollment in clinical trials targeting downstream AMPK/mTOR metabolic axis vulnerabilities.
Preclinical models indicate that STK11-null cancer cells exhibit heightened dependency on glutamine metabolism and focal adhesion kinase (FAK) signaling to survive oxidative stress.
Explore the KiuClavis Platform
Experience dual-lens querying and target space traversal across our interactive tools.